Drug employed for the treatment of early-stage Parkinson’s disease, depression and senile dementia. In normal clinical doses it is a selective irreversible MAO-B inhibitor, however in larger doses it loses its specificity and also inhibits MAO-A. Dietary restrictions are common for MAOI treatments, but special dietary restrictions for lower doses have been found to be unnecessary. However, specific care must be shown in avoiding doses in excess of therapeutic limits, to bypass severe detrimental effects observed with non-selective, irreversible MAOIs. Unfavorable interactions have been noted with common antidepressants, and concurrent administration with Selegiline is not recommended. Also known as: Deprenyl. US trade name: Eldepryl.
SELEGILINE: “Selegiline is employed to combat Parkinson’s and senile dementia.”